AngioDynamics 的 AlphaVac F1885 系统用于治疗肺栓塞获得 FDA 批准。 AngioDynamics receives FDA clearance for AlphaVac F1885 System to treat pulmonary embolism.

AngioDynamics 获得 FDA 批准使用 AlphaVac F1885 系统治疗肺栓塞，增强了其在危急医疗场景中的实用性。 AngioDynamics receives FDA clearance for AlphaVac F1885 System to treat pulmonary embolism, enhancing its utility in critical medical scenarios. 肺栓塞每年影响美国 90 万人，中危患者的死亡率为 3-14%。 Pulmonary embolism affects 900,000 people in the US annually and has a mortality rate of 3-14% for intermediate-risk patients. FDA 扩大的适应症拓展了 AlphaVac F1885 系统的用途，减少了血栓负担并改善了右心室功能。 The expanded FDA indication broadens the use of the AlphaVac F1885 System, reducing thrombus burden and improving right ventricular function.